Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance

Immunochemotherapy induces long-term response in patients with follicular lymphoma. However, toxicity of chemotherapy remains a relevant challenge. The Bruton’s tyrosine kinase inhibitor ibrutinib has shown significant activity in patients with indolent B-cell lymphoma. Combining ibrutinib with obi...

Full description

Saved in:
Bibliographic Details
Main Authors: Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Christian Buske, Andreas Viardot, Ulrich Keller, Ullrich Graeven, Reinhard Marks, Mathias Hänel, Rüdiger Liersch, Jan Dürig, Christiane Pott, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12104
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items